Ozempic vs Wegovy: Same Drug, Different Label

Ozempic and Wegovy are the same drug. Both are semaglutide, made by the same company, Novo Nordisk, and the difference between them is the label, not the molecule. Ozempic is FDA-approved for type 2 diabetes, while Wegovy is FDA-approved for chronic weight management, and the two carry different approved dose ranges. This article explains what that distinction actually means and what it does not; it is educational and not medical or dosing advice.

The one fact that clears up most confusion

Semaglutide is a GLP-1 receptor agonist, a class of medication that mimics a gut hormone to curb appetite, slow gastric emptying (the rate food leaves your stomach), and improve blood-sugar control. Novo Nordisk sells that same semaglutide molecule under two brand names for two different approved purposes.

Think of it like a single active ingredient packaged and approved for two jobs. Ozempic was approved first, for type 2 diabetes (with a later cardiovascular-risk indication). Wegovy came later, approved specifically for chronic weight management in eligible adults and adolescents. Same drug, two doors.

Novo Nordisk also makes a daily oral semaglutide tablet, Rybelsus, which rounds out the family but is a different format and is outside the scope of this comparison.

Ozempic vs Wegovy at a glance

The table below lays out the real differences. Note that the active drug, the maker, and the route are identical; the meaningful distinctions are the approved use and the approved dose range. We are deliberately not listing a titration schedule, because how you reach any dose is a prescriber decision specific to you.

Factor	Ozempic	Wegovy
Active drug	Semaglutide	Semaglutide
Manufacturer	Novo Nordisk	Novo Nordisk
FDA-approved use	Type 2 diabetes (plus cardiovascular risk reduction in some patients)	Chronic weight management in eligible adults and adolescents
Route	Weekly subcutaneous injection	Weekly subcutaneous injection
Approved maintenance dose	Lower maximum than Wegovy	Higher maximum, approved for weight management
Typical insurance angle	Often covered under diabetes benefits	Coverage for weight management varies widely by plan
Side-effect profile	Same molecule, so the same GI-led profile	Same molecule; higher doses may mean more side effects for some
Muscle-loss considerations	Driven by rate of loss and protein, not the brand	Same; faster, larger loss raises the stakes on protein and training

The headline: the only differences that matter are the approved indication, the approved dose ceiling, and how each is covered and accessed. The drug doing the work is the same.

Is Wegovy "stronger" than Ozempic?

This is the most common question, and the honest answer is nuanced. The molecule is identical, so in that sense neither is stronger. But Wegovy is approved up to a higher maintenance dose than Ozempic, and more semaglutide generally produces more appetite suppression and more weight loss. That is why people loosely call Wegovy the stronger one for weight loss.

So the better framing is: it is not a stronger drug, it is a higher approved dose for a specific purpose. In the STEP 1 trial of semaglutide at the 2.4 mg weekly dose used for weight management, participants lost on average about 15 percent of body weight over 68 weeks, versus about 2.4 percent on placebo, according to results published in the New England Journal of Medicine in 2021. That magnitude reflects the higher weight-management dose, not a different molecule.

Your actual dose, on either brand, is something your prescriber determines. We are not going to suggest dose numbers or schedules here, because that is genuinely individual and outside what an educational article should do.

Do they have different side effects?

Because both are semaglutide, the side-effect profile is fundamentally the same. The most common effects are gastrointestinal: nausea, constipation, diarrhea, and vomiting, which tend to be worst during dose increases and ease as the body adjusts. There are also less common but more serious risks listed in the prescribing information for semaglutide, which is why these are prescription medications.

Where the brands can feel different is dose-driven. Since Wegovy reaches a higher maintenance dose, some people experience more side effects on it, but tolerance is highly individual, and plenty of people do fine. The drivers of how you feel are your dose and your rate of weight loss, not the marketing name. For the full rundown, see our complete guide to GLP-1 side effects.

What this means for muscle loss

Here is the part the brand debate usually ignores entirely. Whether the label says Ozempic or Wegovy, semaglutide drives weight loss, and rapid weight loss puts muscle at risk. Research suggests that roughly 25 to 40 percent of weight lost on GLP-1 medications can come from lean mass (a category that includes muscle, water, and organ tissue, not only skeletal muscle), with semaglutide trials often landing toward the higher end of that range. We break the numbers down in how much muscle you lose on Ozempic and Wegovy.

The practical implication is that the brand on the box does not decide whether you keep your muscle. Your protein intake, your resistance training, and your rate of loss do. Because Wegovy's higher approved dose can produce faster, larger loss, the muscle-preservation basics matter more on it, not less. Same drug, same muscle-loss math, scaled by how much weight you are losing.

So which one is "better"?

There is no universal winner, because the choice is rarely about the molecule. It comes down to what you are being treated for, what your prescriber recommends, and what your insurance will cover. Someone with type 2 diabetes and someone seeking weight management are simply pointed at different doors to the same drug.

Availability has also been a moving target in recent years, and coverage rules differ enormously between plans. Those access realities, far more than any difference in the semaglutide itself, are usually what decides which brand a given person ends up on. If you want to compare semaglutide against the other major GLP-1, tirzepatide, our honest semaglutide vs tirzepatide comparison covers that, and the same brand-versus-label logic plays out with Mounjaro vs Zepbound.

Where Myo fits

Whichever semaglutide brand you are on, the thing the label says nothing about is your muscle. Ozempic and Wegovy both track weight and blood sugar in the clinical sense; neither tells you whether the pounds leaving are fat or muscle. That is the gap Myo is built to fill.

Myo logs your dose, brand, and injection sites alongside the data that actually decides whether you keep muscle: protein intake, resistance training, and fat-versus-lean body composition. So if you ever switch between Ozempic and Wegovy, or move to a higher dose, your full history travels with you and you can see whether your muscle is holding. Dose logging, the injection-site map, weight, and the protein ring are free for one medication; the fat-versus-muscle body-composition tracking is part of Premium. If you want to compare the apps that do this, see our best GLP-1 tracking apps, compared.

References

• Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021 (doi:10.1056/NEJMoa2032183).
• US Food and Drug Administration. Prescribing information for Ozempic (semaglutide injection), Novo Nordisk.
• US Food and Drug Administration. Prescribing information for Wegovy (semaglutide injection), Novo Nordisk.
• SURMOUNT-1 and semaglutide body composition analyses on lean-mass share of weight lost. Diabetes, Obesity and Metabolism, 2025 (doi:10.1111/dom.16275); SUSTAIN 8 (PMC6997246).